NCT06508437View on ClinicalTrials.gov

Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

January 21, 2025

Study Completion Date

July 25, 2025

Conditions
Coronary Artery DiseaseInflammatory ResponseAtherosclerosis
Interventions
BIOLOGICAL

Influenza Vaccination

Standard Dose QIV (15µg Hemagglutinin) - VaxigripTetra Suspension for injection, 0,5ml prefilled syringe

Trial Locations (1)

37000

Chru de Trousseau, Tours

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT06508437 - Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease | Biotech Hunter | Biotech Hunter